{"id":"W2152905269","doi":"10.1016/s1470-2045(12)70087-6","title":"Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":953,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Afatinib; Medicine; Erlotinib; Gefitinib; Internal medicine; Clinical endpoint; Hazard ratio; Placebo; Lung cancer; Oncology; Performance status; Chemotherapy; Adenocarcinoma; Randomized controlled trial; Surgery; Cancer; Epidermal growth factor receptor; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001970906,0.002389709,0.005274345,0.0005748309,0.0005625978,0.001466907,0.001067507,0.003178598,0.008294312],"category_scores_gemma":[0.002467905,0.0008116649,0.004036337,0.0005327513,0.001764522,0.00217747,0.0005861023,0.004395033,0.001597802],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008511507,"about_ca_system_score_gemma":0.0008813021,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009586675,"about_ca_topic_score_gemma":0.001782435,"domain_scores_codex":[0.9990678,0.000450717,0.00007865146,0.0001942424,0.000044376,0.0001641996],"domain_scores_gemma":[0.9990797,0.000308523,0.0001829571,0.00007266788,0.00005260613,0.0003034547],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9891192,0.001189731,0.0002088018,0.0005034719,0.0008368677,0.00003129557,0.00003335799,0.0002082355,0.0008754985,0.00008423895,0.000461633,0.006447704],"study_design_scores_gemma":[0.9740978,0.02423607,0.0004443209,0.00002277399,0.0003513021,0.00002696649,0.00001835227,0.0001926261,0.0001178844,0.0001945024,0.0002853753,0.00001211033],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9738818,0.01284208,0.000881224,0.002446824,0.002175529,0.002925971,0.001443496,0.0002542336,0.00314881],"genre_scores_gemma":[0.9884259,0.003068747,0.0007828276,0.001243061,0.0006336986,0.001741018,0.0006707364,0.00002475732,0.003409344],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008294312,"threshold_uncertainty_score":0.02774727,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03765453655497886,"score_gpt":0.403575366148624,"score_spread":0.3659208295936452,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}